BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lu AF28996 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lu AF28996\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07513441-1646@assetmemo.bio
DTSTAMP:20261121T005825Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Lu AF28996: Phase 1 readout est. (NCT07513441)
DESCRIPTION:Lu AF28996\, phase 1\, Parkinson's Disease.\nStudy: A Trial of 
 Lu AF28996 in Participants With Parkinson's Disease (PD)\nEstimated primar
 y completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lu-af28996#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07513441
URL:https://assetmemo.bio/drug/lu-af28996#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514858-1646@assetmemo.bio
DTSTAMP:20261121T005825Z
DTSTART;VALUE=DATE:20281003
DTEND;VALUE=DATE:20281004
SUMMARY:Lu AF28996: Phase 2 readout est. (NCT07514858)
DESCRIPTION:Lu AF28996\, phase 2\, Parkinson's Disease.\nStudy: A Trial Inv
 estigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fl
 uctuations\nEstimated primary completion: 3 October 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lu-af28996#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07514858
URL:https://assetmemo.bio/drug/lu-af28996#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
